MK-677 (Ibutamoren) Monitoring Schedule: Labs & Exams

MK-677 has no FDA-approved monitoring requirement, so the schedule below is built from the handful of published human trials that measured IGF-1, glucose, and related markers, not from a drug label. In a 2-year randomized trial of 65 healthy older adults, MK-677 25 mg daily raised fasting glucose and HbA1c compared with placebo, and some participants with pre-existing impaired glucose tolerance progressed to overt diabetes (Nass et al., 2008). That single trial is the strongest evidence anchor for glucose surveillance during MK-677 use; it does not establish exact thresholds for every patient, and the numeric cutoffs used later in this article for dose adjustment are clinical judgment informed by that signal, not values drawn directly from the trial or from any guideline.

What MK-677 is, and what it is not

MK-677 (ibutamoren) is a small-molecule, orally bioavailable agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor that the natural hormone ghrelin activates. It is distinct from injectable GH-releasing peptides (GHRP-2, GHRP-6, ipamorelin) and from GHRH analogs (CJC-1295, tesamorelin), even though all of these are sometimes marketed together as "GH secretagogues." MK-677 has never received FDA approval for any indication; it has been studied in trials for conditions such as age-related frailty, cachexia, and hip-fracture recovery, and it is sold currently only as a research chemical. Any human use outside of a registered trial is off-label and unsupervised by a manufacturer's label.

How it is thought to work

MK-677 stimulates pulsatile GH release from pituitary somatotrophs by activating GHS-R1a, which in turn raises circulating IGF-1. Early pharmacology work suggested this happens without fully suppressing the body's own GH pulse pattern, but the degree to which MK-677-driven GH release preserves normal pulsatility compared with continuous exogenous GH has not been fully characterized in later human trials. IGF-1 is used as the practical monitoring marker for GH-axis activity because GH itself is difficult to measure reliably (it is secreted in pulses and cleared quickly), while IGF-1 is more stable across a day.

MK-677 also appears capable of affecting cortisol, prolactin, and fasting glucose. The direction of these effects is described in individual trials below, but no published protocol specifies an optimal monitoring interval for cortisol or prolactin specifically, so the schedule below reflects reasonable clinical practice rather than a validated guideline.

What is established, what is plausible, and what is not established

Established from trial data: MK-677 raises IGF-1 in healthy adults; in at least one long-term trial it raised fasting glucose and HbA1c relative to placebo, with some participants progressing to diabetes; in a separate short trial it lowered LDL cholesterol modestly over 6 weeks; it is not FDA-approved for any indication.

Plausible but not well quantified: the size and timing of its effect on prolactin, the degree to which cortisol effects persist beyond the initial weeks of treatment, and whether IGF-1 changes during long-term stable dosing reflect tachyphylaxis versus other causes.

Not established: an official monitoring schedule, a validated stop-threshold for IGF-1, prolactin, or glucose specific to MK-677, and whether pharmacologically elevated IGF-1 from MK-677 carries the same mortality association seen in observational studies of naturally elevated endogenous IGF-1 (Burgers et al., 2011). That mortality data comes from general-population cohorts, not MK-677 users, and should be read as a reason for caution rather than a proven risk figure for this drug.

Why structured labs matter here specifically

GH and IGF-1 influence glucose metabolism, lipid handling, thyroid hormone conversion, fluid balance, and cell proliferation. Because MK-677 has no FDA label, there is no built-in monitoring requirement the way there would be for an approved drug, so any clinician supervising its use has to assemble a schedule from primary trial data rather than from a package insert.

Decision framework: what a given lab result should change

The dosing guidance below was compiled specifically for this mk-677 overview. It has not undergone clinical validation and should be discussed with a qualified physician rather than used as an independent dosing reference.

Baseline labs before starting

Draw these fasting (at least 8 hours) before the first dose.

Tier 1, generally considered necessary:

• IGF-1, interpreted against age-adjusted reference ranges rather than a single universal cutoff (Bidlingmaier et al., 2014)
• Fasting glucose
• HbA1c, with 5.7% or higher already meeting ADA criteria for prediabetes before MK-677 is even started (ADA, 2024)
• Fasting insulin, which together with fasting glucose allows a HOMA-IR estimate; HOMA-IR above roughly 2.5 is a commonly used research marker of insulin resistance, though this cutoff is a convention rather than a value specified in the original HOMA methodology paper (Matthews et al., 1985)
• Prolactin, to document a true baseline since later changes attributable to MK-677 are not well quantified
• Morning cortisol (roughly 8 AM draw), useful mainly as a reference point if symptoms suggestive of cortisol excess appear later

Tier 2, reasonable to add:

• Comprehensive metabolic panel (liver enzymes, renal function, electrolytes)
• Lipid panel, since a short trial in obese adults found an LDL reduction of roughly 10% over 6 weeks of MK-677 25 mg/day (Svensson et al., 1998)
• TSH and free T4, because GH-axis activity can affect peripheral T4-to-T3 conversion; clinical guidelines for GH replacement in diagnosed GH deficiency recommend thyroid monitoring during GH-axis therapy, though such guidance addresses recombinant GH replacement, not off-label MK-677 use, and the recommendation is being extended here by analogy
• CBC with differential

Tier 3, situational:

• PSA in men over 40, particularly with a family history of prostate cancer, given the general association between IGF-1 signaling and prostate cell proliferation in observational literature
• DEXA scan if a skeletal goal is part of the reason for use

The 4-to-6-week recheck

Fasting labs, drawn at least 12 hours after the last dose so the result reflects a trough rather than the acute post-dose GH/IGF-1 peak.

• IGF-1: compare to the baseline age-adjusted range. A result meaningfully above the upper limit of normal is a reasonable trigger to discuss dose reduction with a supervising clinician; there is no single validated percentage cutoff from trial data, so this is a judgment call.
• Fasting glucose and insulin: compare directly to baseline. A clear upward trend, or crossing into the impaired-fasting-glucose range, is a reason to discuss dose reduction or adding standard glucose-management measures.
• Prolactin: a marked rise from baseline, or a value clearly outside standard lab reference ranges, warrants a repeat test and clinical evaluation rather than assuming it is drug-related.
• Clinical exam: blood pressure, check for peripheral edema, and ask about new joint pain or carpal-tunnel-type symptoms, all of which are plausible with GH-mediated fluid retention.

The 12-week assessment

By 12 weeks, IGF-1 typically plateaus and HbA1c reflects the full period on therapy, which makes this visit a natural decision point.

• Repeat the Tier 1 panel (IGF-1, fasting glucose, HbA1c, fasting insulin, prolactin).
• In the Nass et al. cohort, participants whose glucose measures worsened progressively over the study period were the ones who later showed clearer glucose intolerance; this supports treating a rising HbA1c trend at 12 weeks as clinically meaningful, even though the trial did not define an exact "stop at this number" rule (Nass et al., 2008). Verification of exact percentage figures from this trial is recommended before quoting them to a patient, since this article summarizes the trial's direction of effect rather than reproducing its full numeric results table.
• Repeat lipid panel; a favorable LDL trend supports continuing, while a new rise in triglycerides deserves attention given the link between insulin resistance and hepatic triglyceride output.
• Repeat TSH; a suppressed TSH with a rising free T3 may indicate accelerated peripheral T4-to-T3 conversion, which matters most for patients already on thyroid hormone replacement.

Ongoing monitoring, roughly every 3 to 6 months

Once stable, IGF-1, fasting glucose, HbA1c, and fasting insulin form the minimum ongoing panel, with prolactin and a metabolic panel at least every 6 months.

An unexpected drop in IGF-1 during otherwise stable dosing should not be assumed to reflect tachyphylaxis; adherence, product sourcing and quality (relevant for an unregulated research compound), and unrelated medical causes should all be considered first.

If skeletal health is part of the treatment goal, an annual DEXA scan is reasonable. A trial combining MK-677 with alendronate in postmenopausal women with osteoporosis found increases in bone turnover markers within weeks, but that trial specifically studied osteoporotic postmenopausal women on a combination regimen, and its findings should not be generalized to other populations or to MK-677 used alone (Murphy et al., 2001).

Findings that warrant same-day clinical attention

• Fasting glucose ≥126 mg/dL on two separate draws, or HbA1c ≥6.5%: meets ADA diagnostic criteria for diabetes; this is a reason to stop MK-677 and pursue standard diabetes evaluation (ADA, 2024).
• IGF-1 far above the age-adjusted upper limit of normal: sustained high endogenous IGF-1 has been associated with increased all-cause mortality in general-population observational data, which is a reason for caution even though this association has not been directly studied in MK-677 users specifically (Burgers et al., 2011).
• Markedly elevated prolactin: warrants ruling out a prolactinoma with pituitary imaging before attributing the finding to MK-677.
• New persistent headache or visual field changes: rare, but any GH-axis stimulant could theoretically affect a pre-existing pituitary lesion; this warrants urgent evaluation and pituitary MRI, not routine follow-up.

Populations that need extra attention

• Adults over 60 appeared to have a higher rate of fasting glucose above 100 mg/dL in the Nass et al. cohort compared with younger participants, supporting more frequent glucose checks in this age group (Nass et al., 2008).
• Patients on concurrent testosterone replacement therapy should have hematocrit checked at each visit, since both GH-axis stimulation and testosterone can independently raise red blood cell mass.
• Patients with a personal or strong family history of prostate or colorectal cancer should discuss whether MK-677 is appropriate at all outside a supervised research protocol. Clinical guidance for GH-axis treatment in a different population (adult GH deficiency) advises against GH therapy in patients with active malignancy; whether this extends directly to MK-677 has not been separately studied, but the underlying caution about IGF-1 signaling and cell proliferation is reasonable to apply.

A practical timeline

• Week 0: Tier 1 and Tier 2 labs, plus a physical exam including blood pressure and baseline weight.
• Week 4 to 6: IGF-1, fasting glucose, fasting insulin, prolactin; blood pressure and edema check.
• Week 12: Full Tier 1 panel plus HbA1c, lipids, TSH; this is the main continue-or-stop decision point.
• Every 3 months thereafter: IGF-1, fasting glucose, HbA1c, fasting insulin; metabolic panel and prolactin at least every 6 months.
• Annually: DEXA if skeletal goals apply, PSA in men over 40, full physical exam.

Patients whose fasting glucose stays under 100 mg/dL and whose IGF-1 remains within the age-adjusted normal range through the first year may reasonably move most labs to every 6 months, but fasting glucose specifically is worth keeping quarterly given the metabolic signal seen in the Nass et al. trial.

When to seek care outside this schedule

Chest pain, sudden vision changes, severe headache, signs of an allergic reaction, or symptoms of a hyperglycemic crisis (extreme thirst, confusion, rapid breathing) are reasons to seek urgent or emergency care rather than waiting for a scheduled lab draw.